Retatrutide, a new dual stimulator of the GLP-1 target and glucose-dependent released polypeptide (GIP) target, is demonstrating promising outcomes in initial patient trials . Ongoing research suggests https://bookmarkyourpage.com/story6876284/retatrutide-emerging-studies-and-projected-clinical-roles